📊 ELVN Key Takeaways
Is ELVN a Good Investment? Thesis Analysis
Enliven Therapeutics is a pre-revenue biopharmaceutical company burning significant cash with negative operating margins of -119.7M and declining net losses, indicating the company is in early development stages without commercial product generation. While the balance sheet shows strong liquidity (28.66x current ratio) and minimal debt, the company is consuming approximately $70M in operating cash annually with only $98.9M in cash reserves, providing limited runway without achieving revenue milestones or securing additional financing.
Why Buy ELVN? Key Strengths
- Strong balance sheet with $459.6M stockholders equity and minimal debt (0.00x debt-to-equity)
- Excellent liquidity position with $98.9M cash and 28.66x current ratio providing financial flexibility
- Net losses improving year-over-year (declining 16.5% from prior period) suggesting operational progress toward development goals
ELVN Investment Risks to Consider
- Zero revenue generation indicating no commercial products on market and high execution risk for clinical programs
- Negative operating cash flow of -$70.3M annually with limited cash runway of approximately 1.4 years at current burn rate without revenue
- Negative ROE (-22.6%) and ROA (-21.8%) reflecting value destruction with no clear path to profitability; typical pre-revenue biotech development risk
- 23 Form 4 insider filings in 90 days suggesting potential insider selling or equity compensation dilution
Key Metrics to Watch
- Cash burn rate and time to cash depletion; need for future financing rounds
- Clinical trial progress and regulatory milestones for lead programs
- Changes in cash position and additional capital raises that extend runway
ELVN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 28.66x current ratio provides a solid financial cushion.
ELVN Profitability Ratios
ELVN vs Healthcare Sector
How Enliven Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELVN Overvalued or Undervalued?
Based on fundamental analysis, Enliven Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELVN Balance Sheet & Liquidity
ELVN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Enliven Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.89 indicates the company is currently unprofitable.
ELVN Growth Metrics (YoY)
ELVN Capital Allocation
ELVN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Enliven Therapeutics, Inc. (CIK: 0001672619)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELVN
What is the AI rating for ELVN?
Enliven Therapeutics, Inc. (ELVN) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELVN's key strengths?
Claude: Strong balance sheet with $459.6M stockholders equity and minimal debt (0.00x debt-to-equity). Excellent liquidity position with $98.9M cash and 28.66x current ratio providing financial flexibility.
What are the risks of investing in ELVN?
Claude: Zero revenue generation indicating no commercial products on market and high execution risk for clinical programs. Negative operating cash flow of -$70.3M annually with limited cash runway of approximately 1.4 years at current burn rate without revenue.
What is ELVN's revenue and growth?
Enliven Therapeutics, Inc. reported revenue of N/A.
Does ELVN pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
Where can I find ELVN SEC filings?
Official SEC filings for Enliven Therapeutics, Inc. (CIK: 0001672619) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELVN's EPS?
Enliven Therapeutics, Inc. has a diluted EPS of $-1.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELVN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Enliven Therapeutics, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELVN stock overvalued or undervalued?
Valuation metrics for ELVN: ROE of -22.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELVN stock in 2026?
Our dual AI analysis gives Enliven Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELVN's free cash flow?
Enliven Therapeutics, Inc.'s operating cash flow is $-70.3M, with capital expenditures of $158.0K.
How does ELVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -22.6% (avg: 15%), current ratio 28.66 (avg: 2).